Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Synthetic Biologics Inc. SYN

Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The...

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NYSEAM:SYN)

Fundamentals Snapshot (NYSEAM:SYN)

Current News (NYSEAM:SYN)

Synthetic Biologics Announces Presentation at SIOP International Society of Pediatric Oncology on New Preclinical Data Supporting Evaluation of VCN-01 and Topotecan for the Treatment of Refractory Retinoblastoma

GlobeNewswire 2 days ago

Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

GlobeNewswire 5 days ago

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

GlobeNewswire September 5, 2022

Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results

GlobeNewswire August 11, 2022

Synthetic Biologics to Participate in the BTIG Biotechnology Conference 2022

GlobeNewswire August 4, 2022

Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Financial Results

GlobeNewswire August 4, 2022

Synthetic Biologics Announces $3 Million Private Placement of Convertible Preferred Stock

GlobeNewswire July 29, 2022

Synthetic Biologics Announces Reverse Stock Split

GlobeNewswire July 15, 2022

Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results

GlobeNewswire May 16, 2022

Opinion & Analysis (NYSEAM:SYN)

No current opinion is available.

Bullboard Posts (NYSEAM:SYN)

RE:RE:RE:Watching for some Volume increase.....

What a sweet day....Is everyone happy????
Iseneschal - January 15, 2021

RE:RE:Watching for some Volume increase.....

Iseneschal - January 13, 2021

RE:Watching for some Volume increase.....

The "Stars are lining up" or should I say.... The moving averages are are in a perfect scenario for a big move! JMHO...
Iseneschal - January 13, 2021

Watching for some Volume increase.....

This should quickly "gap fill" to $0.84
Iseneschal - January 13, 2021

RE:Added this a.m.......

Sure does pay to buy those dips.....now over $0.80 and heading for an alltime high....soon!
Iseneschal - January 13, 2021

Added this a.m.......

Cheaper than a Slurpee. JMHO Cheers!
Iseneschal - January 13, 2021